article thumbnail

Sanofi Wins FDA Nod for Merilog, First Rapid-Acting Insulin Biosimilar

XTalks

The FDA has approved Sanofis Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar product for the treatment of diabetes. Merilog is a biosimilar to Novo Nordisks NovoLog, a widely used rapid-acting insulin aspart. Insulin, a hormone produced by the pancreas, allows glucose to enter cells for energy.

Insulin 59
article thumbnail

Medtronic Expands Two Insulin Pump Recalls, Including One Over Cybersecurity Concerns

XTalks

Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks. The medtech giant has also expanded another Class I recall of the retainer rings on its 600 series insulin pumps.

Insulin 128
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oramed hits oral insulin clinical trial milestone

BioPharma Reporter

Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the worldâs first Phase 3 study of oral insulin under FDA approved protocols.

Insulin 127
article thumbnail

Dopamine regulates insulin secretion through a complex of receptors, finds new study

Scienmag

Diabetes is a lifelong, chronic health condition caused by abnormalities in the body’s production and use of the hormone insulin. Research has shown that the feel-good hormone, dopamine (DA), plays a key role in how the body regulates the production of insulin.

Insulin 72
article thumbnail

FTC to sue three largest PBMs over drug price practices: WSJ

Bio Pharma Dive

Antitrust regulators are set to file suit against CVS Caremark, Express Scripts and Optum Rx over how they negotiate discounts for drugs, including insulin, per the report.

Insulin 164
article thumbnail

STAT+: ‘Patchy efforts’ by major insulin makers mean access lags in many poor countries

STAT News

The three companies that dominate the global market for insulin have launched various programs to expand the reach of their medicines in dozens of low and middle-income countries — but their efforts remain patchy and equitable access consequently remains out of reach, according to a new analysis.

Insulin 111
article thumbnail

GLP-1 receptor agonists could hold promise for opioid use disorder treatment

Pharmaceutical Technology

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.

Insulin 162